Published in J Acquir Immune Defic Syndr on August 01, 2011
Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund. Global Health (2013) 0.93
Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials (2014) 0.78
HIV testing for children in resource-limited settings: what are we waiting for? PLoS Med (2010) 1.87
Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis (2012) 1.82
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis (2012) 1.46
Transition from bare metal to drug eluting stenting in contemporary US practice: effect on incidence and predictors of clinically driven target lesion revascularization. Catheter Cardiovasc Interv (2007) 1.42
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics (2007) 1.39
Perspectives on introduction and implementation of new point-of-care diagnostic tests. J Infect Dis (2012) 1.33
Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol (2005) 1.14
Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation (2005) 0.98
Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res (2014) 0.93
Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay. PLoS One (2009) 0.93
Correlation between HIV-Specific CD8 cell production of interferon- gamma and plasma levels of HIV RNA in perinatally infected pediatric populations. J Infect Dis (2004) 0.92
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. PLoS Med (2013) 0.89
Determinants of HIV drug resistance and public health implications in low- and middle-income countries. Antivir Ther (2012) 0.88
Phosphorylation-induced conformational changes in a mitogen-activated protein kinase substrate. Implications for tyrosine hydroxylase activation. J Biol Chem (2002) 0.86
A reverse transcriptase assay for early diagnosis of infant HIV infection in resource-limited settings. J Trop Pediatr (2007) 0.84
Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis (2002) 0.83
Treatment optimization: an outline for future success. Curr Opin HIV AIDS (2013) 0.78
Modeling the Impact of Retention Interventions on Mother-to-Child Transmission of HIV: Results From INSPIRE Studies in Malawi, Nigeria, and Zimbabwe. J Acquir Immune Defic Syndr (2017) 0.75
Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr (2017) 0.75
Translating Technical Support Into Country Action: The Role of the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers, and Children in the Global Plan Era. J Acquir Immune Defic Syndr (2017) 0.75
Pediatric Treatment Scale-Up: The Unfinished Agenda of the Global Plan. J Acquir Immune Defic Syndr (2017) 0.75
Optimal Anti-Retroviral Prophylaxis in Infants At High-Risk of Acquiring Human Immunodeficiency Virus: A Systematic Review. Pediatr Infect Dis J (2017) 0.75